Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies | July 21, 2015

July 21, 2015 "” Two companion papers published in Academic Emergency Medicine  address the question of when it is...

platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies | July 13, 2015

July 13, 2015 - Researchers have created tiny gel particles that can perform the same essential functions as...

idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies | July 07, 2015

July 7, 2015 - Results from an interim analysis of the...

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Technology | June 22, 2015

June 22, 2015 - The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug...

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
Feature | Antiplatelet and Anticoagulation Therapies | June 10, 2015

June 9, 2015 - AstraZeneca announced full results from the...

rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015
News | May 21, 2015

May 21, 2015 — Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI
Feature | Antiplatelet and Anticoagulation Therapies | May 18, 2015

May 18, 2015 — A risk assessment algorithm...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI
News | May 18, 2015

May 18, 2015 — Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI
Feature | May 15, 2015

May 15, 2015 — Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing...

News | May 14, 2015

May 14, 2015 — A new study reports that antiplatelet drug ...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed
Feature | May 06, 2015

May 6, 2015 — People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart...

News | May 01, 2015

One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called...

Brilinta, AstraZeneca, FDA, sNDA, PEGASUS-TIMI 54, new indication
News | April 30, 2015

April 30, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...

Overlay Init